CA3112953A1 - Tlr8 agonist - Google Patents
Tlr8 agonist Download PDFInfo
- Publication number
- CA3112953A1 CA3112953A1 CA3112953A CA3112953A CA3112953A1 CA 3112953 A1 CA3112953 A1 CA 3112953A1 CA 3112953 A CA3112953 A CA 3112953A CA 3112953 A CA3112953 A CA 3112953A CA 3112953 A1 CA3112953 A1 CA 3112953A1
- Authority
- CA
- Canada
- Prior art keywords
- compound
- isomer
- acceptable salt
- group
- tlr8
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811094969.4 | 2018-09-19 | ||
| CN201811094969 | 2018-09-19 | ||
| PCT/CN2019/106687 WO2020057604A1 (zh) | 2018-09-19 | 2019-09-19 | Tlr8激动剂 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3112953A1 true CA3112953A1 (en) | 2020-03-26 |
Family
ID=69888288
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3112953A Pending CA3112953A1 (en) | 2018-09-19 | 2019-09-19 | Tlr8 agonist |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12054482B2 (https=) |
| EP (1) | EP3854794B1 (https=) |
| JP (1) | JP7498702B2 (https=) |
| KR (1) | KR102856089B1 (https=) |
| CN (2) | CN112805283B (https=) |
| AU (1) | AU2019344868B2 (https=) |
| CA (1) | CA3112953A1 (https=) |
| ES (1) | ES2999323T3 (https=) |
| PH (1) | PH12021550601A1 (https=) |
| SG (1) | SG11202102641RA (https=) |
| WO (1) | WO2020057604A1 (https=) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202102641RA (en) | 2018-09-19 | 2021-04-29 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Tlr8 agonist |
| EP4122931B1 (en) * | 2020-03-18 | 2025-07-02 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Crystalline form of tlr8 agonist |
| CN116472047B (zh) * | 2021-11-05 | 2025-06-17 | 中国医药研究开发中心有限公司 | 芳胺类衍生物及其制备方法和医药用途 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0503506D0 (en) | 2005-02-21 | 2005-03-30 | 4 Aza Bioscience Nv | Substituted pyrido(2,3-d) pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders |
| PT2268618E (pt) | 2008-03-03 | 2015-10-12 | Novartis Ag | Compostos e composições moduladores da actividade tlr |
| SG194852A1 (en) | 2011-05-18 | 2013-12-30 | Janssen R & D Ireland | Quinazoline derivatives for the treatment of viral infections and further diseases |
| WO2013022766A1 (en) | 2011-08-05 | 2013-02-14 | Flynn Gary A | Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors |
| EP2925729B1 (en) | 2012-11-16 | 2017-10-18 | Janssen Sciences Ireland UC | Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections |
| WO2016141092A1 (en) | 2015-03-04 | 2016-09-09 | Gilead Sciences, Inc. | Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds |
| EP3507288B1 (en) | 2016-09-02 | 2020-08-26 | Gilead Sciences, Inc. | 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators |
| CN109923106B (zh) | 2016-09-02 | 2022-09-13 | 吉利德科学公司 | toll样受体调节剂化合物 |
| SG11202102641RA (en) | 2018-09-19 | 2021-04-29 | Chia Tai Tianqing Pharmaceutical Group Co Ltd | Tlr8 agonist |
-
2019
- 2019-09-19 SG SG11202102641RA patent/SG11202102641RA/en unknown
- 2019-09-19 ES ES19862693T patent/ES2999323T3/es active Active
- 2019-09-19 AU AU2019344868A patent/AU2019344868B2/en active Active
- 2019-09-19 CN CN201980052513.8A patent/CN112805283B/zh active Active
- 2019-09-19 KR KR1020217011377A patent/KR102856089B1/ko active Active
- 2019-09-19 US US17/276,920 patent/US12054482B2/en active Active
- 2019-09-19 EP EP19862693.9A patent/EP3854794B1/en active Active
- 2019-09-19 JP JP2021515104A patent/JP7498702B2/ja active Active
- 2019-09-19 WO PCT/CN2019/106687 patent/WO2020057604A1/zh not_active Ceased
- 2019-09-19 CN CN202211301510.3A patent/CN115650979A/zh active Pending
- 2019-09-19 CA CA3112953A patent/CA3112953A1/en active Pending
-
2021
- 2021-03-17 PH PH12021550601A patent/PH12021550601A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP7498702B2 (ja) | 2024-06-12 |
| EP3854794A1 (en) | 2021-07-28 |
| JP2022501350A (ja) | 2022-01-06 |
| AU2019344868A1 (en) | 2021-04-15 |
| AU2019344868B2 (en) | 2024-06-27 |
| ES2999323T3 (en) | 2025-02-25 |
| US12054482B2 (en) | 2024-08-06 |
| CN112805283A (zh) | 2021-05-14 |
| WO2020057604A1 (zh) | 2020-03-26 |
| SG11202102641RA (en) | 2021-04-29 |
| PH12021550601A1 (en) | 2021-11-29 |
| KR102856089B1 (ko) | 2025-09-04 |
| CN115650979A (zh) | 2023-01-31 |
| KR20210060567A (ko) | 2021-05-26 |
| US20210371414A1 (en) | 2021-12-02 |
| EP3854794A4 (en) | 2022-06-15 |
| CN112805283B (zh) | 2022-09-20 |
| EP3854794B1 (en) | 2024-11-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3962602B1 (en) | Itaconic acid derivatives and uses thereof in treating an inflammatory disease or a disease associated with an undesirable immune response | |
| EP4200275A2 (en) | Fumarate derivatives and their medical use | |
| US20230381132A1 (en) | Novel compounds | |
| US20230399289A1 (en) | Itaconic acid derivatives | |
| CA3112953A1 (en) | Tlr8 agonist | |
| US20240360067A1 (en) | Derivatives of itaconic acid and their use as anti-inflammatory agents | |
| US12071435B2 (en) | TLR8 agonist | |
| EP4634167A1 (en) | Substituted pyridines for use in treating or preventing inflammatory diseases or diseases associated with an undesirable immune response | |
| RU2800877C2 (ru) | Агонист tlr8 | |
| HK40048022A (en) | Tlr8 agonist | |
| HK40048022B (en) | Tlr8 agonist | |
| US12516057B2 (en) | Crystalline form of TLR8 agonist | |
| TW202136195A (zh) | 新穎之化合物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220909 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20240829 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241211 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250206 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST Effective date: 20250317 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250319 |
|
| R00 | Party data change recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R119 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUEST Effective date: 20250320 Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R00-R116 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUEST Effective date: 20250320 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250320 |
|
| R19 | Request for party data change rejected |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R19-R122 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUIREMENTS DETERMINED NOT COMPLIANT Effective date: 20250508 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250508 |
|
| R17 | Change to representative recorded |
Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R17-R121 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REVOCATION OF AGENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250514 Free format text: ST27 STATUS EVENT CODE: A-2-2-R10-R17-R117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPOINTMENT OF AGENT REQUIREMENTS DETERMINED COMPLIANT Effective date: 20250514 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20250514 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250611 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250611 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 6TH ANNIV.) - STANDARD Year of fee payment: 6 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250702 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250702 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260211 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260211 |